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The National Antimicrobial Resistance Monitoring Sys-
tem monitors susceptibility among Enterobacteriaceae in 
humans in the United States. We studied isolates exhibiting 
decreased susceptibility to quinolones (nalidixic acid MIC 
>32 μg/mL or ciproﬂ  oxacin MIC >0.12 μg/mL) and extend-
ed-spectrum cephalosporins (ceftiofur or ceftriaxone MIC 
>2  μg/mL) during 1996–2004. Of non-Typhi Salmonella, 
0.19% (27/14,043) met these criteria: 11 Senftenberg; 6 Ty-
phimurium; 3 Newport; 2 Enteridis; and 1 each Agona, Haifa, 
Mbandaka, Saintpaul, and Uganda. Twenty-six isolates had 
gyrA mutations (11 at codon 83 only, 3 at codon 87 only, 12 
at both). All Senftenberg isolates had parC mutations (S80I 
and T57S); 6 others had the T57S mutation. The Mbandaka 
isolate contained qnrB2. Eight isolates contained blaCMY-2; 1 
Senftenberg contained blaCMY-23. One Senftenberg and 1Ty-
phimurium isolate contained blaSHV-12; the Mbandaka isolate 
contained  blaSHV-30. Nine Senftenberg isolates contained 
blaOXA-1; 1 contained blaOXA-9. Further studies should address 
patient outcomes, risk factors, and resistance dissemination 
prevention strategies.
A
lthough antimicrobial agents are not indicated for un-
complicated Salmonella infections, ﬂ  uoroquinolones 
and extended-spectrum cephalosporins are potentially life-
saving treatments for extraintestinal infections (1). The 
National Antimicrobial Resistance Monitoring System 
(NARMS) has monitored antimicrobial drug resistance 
among enteric pathogens since 1996. NARMS has docu-
mented decreased susceptibility to each of these drug class-
es, in most instances among separate serotypes (2). Histori-
cally, decreased susceptibility to ﬂ  uoroquinolones, which 
can be monitored by tracking resistance to nalidixic acid, 
has been noted among Salmonella serotypes (ser.) Typhi, 
Senftenberg, and Virchow (2,3). More recently, decreased 
susceptibility to ﬂ  uoroquinolones has been noted among 
Salmonella ser. Enteritidis (4). Decreased ﬂ  uoroquinolone 
susceptibility has also been seen among nalidixic acid–sus-
ceptible isolates (5). Extended-spectrum cephalosporin 
resistance was noted among 15 non-Typhi Salmonella 
NARMS isolates (including 12 ser. Typhimurium) during 
1996–1998 (6). In all instances, extended-spectrum cepha-
losporin resistance was the result of blaCMY-2, a class C 
plasmid-encoded ampC gene (7). In addition to conferring 
resistance or decreased susceptibility to extended-spec-
trum cephalosporins such as ceftiofur and ceftriaxone, this 
gene also confers resistance to ampicillin (AMP), amoxil-
lin-clavulanate, cephalothin, and cefoxitin. This AmpC re-
sistance phenotype has been seen in strains of Salmonella 
ser. Newport along with resistance to other drugs includ-
ing chloramphenicol, streptomycin, sulfamethoxazole, and 
tetracycline. This MDRAmpC strain rose from 1% (1/77) 
of Salmonella ser. Newport submissions in 1998 to 25% 
(31/124) in 2001 (4). CMY β-lactamases are largely re-
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sponsible for extended-spectrum cephalosporin resistance 
among Salmonella ser. Newport, Typhimurium, and others 
isolated in North America (6,8).
Coresistance to ﬂ  uoroquinolones and extended-spec-
trum cephalosporins would limit therapeutic options for 
Salmonella infections. Decreased susceptibility to both 
drug classes was identiﬁ  ed in Thailand in 1993 (ser. Ana-
tum, Derby, Enteritidis, Typhimurium, Weltevreden, and I 
4,5,12:i:-) (9), the United Kingdom in 1998 (ser. Senften-
berg, Typhimurium, and Virchow) (10), Belgium as early 
as 2001 (ser. Virchow) (11), India in 2002 (ser. Typhi) (12), 
the United States in 2002 (ser. Mbandaka) (13), France in 
2003 (11), and Taiwan in 2004 (ser. Choleraesuis, Cairo, 
and Kaduna) (14). In the United States, 27 (4.6%) of 588 
Salmonella ser. Typhimurium isolates (clinical and slaugh-
ter) obtained from food animals in 1999 were resistant 
to ceftiofur and nalidixic acid: 22 (81%) from turkeys, 4 
(15%) from horses, and 1 (4%) from cattle (15).
To understand coresistance to both antimicrobial class-
es among Salmonella isolates obtained from humans in the 
United States, we studied the NARMS human collection 
from 1996 through 2004, looking for decreased susceptibil-
ity to quinolones and extended-spectrum cephalosporins. 
Information for some of the isolates has been presented 
elsewhere (3,13,16–18). We present the molecular epide-
miology of this phenotype and mechanisms responsible for 
its decreased susceptibility.
Materials and Methods
Isolates and Antimicrobial Drug Susceptibility Testing
NARMS-participating state and local public health 
laboratories submitted non-Typhi Salmonella isolates to 
the Centers for Disease Control and Prevention (CDC) for 
antimicrobial susceptibility testing: every 10th isolate from 
1996 through 2002 and every 20th isolate from 2003 to pres-
ent. Serotypes were determined by the submitting laboratory 
and, for this study, were conﬁ  rmed by the CDC National Sal-
monella Reference Laboratory according to the Kaufmann-
White scheme as described (19). MICs were determined by 
using broth microdilution (Sensititre, Westlake, OH, USA). 
Isolates exhibiting an amikacin MIC >4 μg/mL were con-
ﬁ  rmed by Etest (ABBiodisk, Piscataway, NJ, USA). Crite-
ria for decreased susceptibility to quinolones and extended-
spectrum cephalosporins were as follows: MIC >32 μg/mL 
for nalidixic acid or >0.12 μg/mL for ciproﬂ  oxacin and >2 
μg/mL for ceftiofur or ceftriaxone. Susceptibility testing 
was performed according to manufacturer’s instructions 
by using control strains Escherichia coli ATCC25922 and 
ATCC35218, and Klebsiella pneumoniae ATCC700603 (for 
extended-spectrum β-lactamase [ESBL] conﬁ  rmation only). 
When available, Clinical Laboratory Standards Institute 
(CLSI) guidelines were used for interpretation (20).
Isoelectric Focusing for β-Lactamases
The methods of Rasheed et al. were used with modi-
ﬁ  cation  (21). Three-hour trypticase soy broth cultures 
(grown at 37°C with shaking at 300 rpm) were pelleted, re-
suspended in 0.2% sodium acetate to 5% of original culture 
volume, and freeze-thawed 4 times (dry ice/ethanol bath 
and 37°C water bath). Preparations were diluted 2-fold with 
distilled water and swirled occasionally on ice for 30 min. 
Supernatants were collected after centrifugation (30 min at 
20,200× g), and 3–5-μL aliquots were resolved for 1.5 h 
on Ampholine PAGplate polyacrylamide gels, pH 3.5–9.5 
(APBiotech, Piscataway, NJ, USA). Gels were stained with 
nitroceﬁ  n (500 μg/mL; Becton Dickinson, Franklin Lakes, 
NJ, USA). Isoelectric points (pIs) were estimated by com-
parison with the following standard β-lactamases: TEM-12 
(pI 5.25), KPC-2 (pI 6.7), SHV-3 (pI 7.0), SHV-18 (pI 7.8), 
and MIR-1 (pI 8.4). 
PCR Detection of Antimicrobial 
Drug Resistance Genes
Presence of qnr genes was determined by using 
PCR with primers QP1 and QP2 for qnrA (22), FQ1 and 
FQ2 for qnrB ( 23), and 5′-ATGGAAACCTACAAT-
CATAC-3′ and 5′-AAAAACACCTCGACTTAAGT-3′ 
for qnrS. The qnrB allele was determined by ampliﬁ  ca-
tion and sequencing with primers FQ1 and FQ2. Screen-
ing for aac(6′)-Ib-cr was performed as described (24). 
Primer pairs used for ampliﬁ  cation of β-lactamase genes 
were:  blaCMY (5′-ATGATGAAAAAATCGTTATGC-3′)
and (5′-TTGCAGCTTTTCAAGAATGCGC-3′) (25); 
blaOXA-1 (5′-AATGGCACCAGATTCAACTT-3′) and 5′-
CTTGGCTTTTATGCTTGATG-3′) (26); blaTEM (5′-TTC
TTGAAGACGAAAGGGC-3′) and (5′-ACGCTCAGTG
GAACGAAAAC-3′) (27); and blaSHV (5′-GGTTATGCGT
TATATTCGCC-3′) and (5′-TTAGCGTTGCCAGTGCTC-
3′) (28) or at Lahey (5′-GCCGGGTTATTCTTATTTGTC-
3′) and (5′-TCTTTCCGATGCCGCCGCCAG-3′) (29). 
blaCTX-M genes were screened by using a multiplex PCR 
assay (30).
DNA Sequencing
Full-length sequences were obtained for β-lactamase 
genes. A 255-bp region covering the quinolone-resistant 
determining region (QRDR) of gyrA (Met52 to Leu137) 
was ampliﬁ  ed by using primers gyrA1: 5′-CATGAACG-
TATTGGGCAATG-3′ and gyrA2: 5′-AGATCGGCCAT-
CAGTTCGTG-3′. QRDRs of gyrB, parC, and parE were 
ampliﬁ   ed and sequenced by using previously described 
primers (31), except primers parCF (5′-ATCGTGCGTT
GCCGTTTAT-3′) and parCR (5′-GCCGCTTTCGC
CACTTC-3′) were used to enhance coverage of parC. Am-
plicons were sequenced by using ABI Big-Dye 3.1 chemis-
try and ABI 3730XL automated DNA sequencers (PE Bio-
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systems, Foster City, CA, USA). Analysis was performed 
by using BioEdit (www.mbio.ncsu.edu/BioEdit/bioedit.
htmL) or SeqMan software (DNAStar, Madison, WI, 
USA). QRDR sequences of gyrA, gyrB, parC, and parE 
were compared with those of Salmonella ser. Typhimuri-
um LT2 (GenBank accession nos. AE008801, AE008878, 
AE008846, and AE008846, respectively).
Pulsed-Field Gel Electrophoresis (PFGE)
PFGE was performed as previously described (32). 
Isolates that produced indistinguishable patterns with XbaI 
(Roche Molecular Biochemicals, Indianapolis, IN, USA) 
were restricted with BlnI. Patterns were analyzed by us-
ing the BioNumerics version 4.0 software (Applied Maths, 
Sint-Martens-Latem, Belgium) and compared by unweight-
ed pair group method with averages by using the Dice coef-
ﬁ  cient with a 1.5% band position tolerance window. The 
DNA sequence and deduced amino acid sequence for the 
Salmonella ser. Senftenberg blaCMY-23 gene were assigned 
GenBank accession no. DQ463751.
Results
Decreased susceptibility to quinolones and extended-
spectrum cephalosporins was ﬁ  rst noted in NARMS data 
in 1997 and represented 0.19% (27/14,043) of non-Typhi 
Salmonella from 1996 through 2004 (Table 1). Salmonella 
ser. Senftenberg was the most frequent serotype (n = 11), 
followed by Typhimurium (n = 6), Newport (n = 3), and 
Enteritidis (n = 2). The phenotype was found in 9 different 
serotypes in 13 states (Table 2).
PFGE comparison by XbaI and, if applicable, BlnI 
restriction showed that 15/27 Salmonella isolates differed 
by >1 band. No indistinguishable patterns among differ-
ent  Salmonella serotypes were identiﬁ   ed. Of the 3 ser. 
Newport isolates tested, 2 (AM15201 and AM21465) had 
indistinguishable XbaI patterns but different BlnI patterns 
(87.51% similarity). The 2 Enteritidis isolates (AM09124 
and AM15266) were indistinguishable by both enzymes. 
Of the 11 ser. Senftenberg isolates, 5 exhibited unique XbaI 
PFGE patterns, while the remaining 6 were separated into 2 
groups with indistinguishable XbaI PFGE patterns (group 
1: AM06960, AM08081, AM16094, and AM19422; group 
2: AM20227 and AM20256). BlnI restriction demonstrated 
that AM19422 differed from the other group 1 isolates by 
a single band difference (97.44% similarity). PFGE results 
for some of the Senftenberg isolates are described else-
where (16,18). All Typhimurium isolates exhibited unique 
XbaI PFGE patterns (77%–93% similarity).
Antimicrobial drug susceptibility results are presented 
in Table 3. For nalidixic acid, 25 isolates exhibited an MIC 
>32 μg/mL, and 2 (Mbandaka and Newport) had an MIC of 
16 μg/mL. For ciproﬂ  oxacin, MICs of 0.12–0.5 μg/mL were 
found for all isolates except the 11 Senftenberg, for which 
the MIC was >4 μg/mL. For ceftiofur, 14 isolates exhibited 
resistance (MIC >8 μg/mL). For ceftriaxone, 2 isolates ex-
hibited resistance according to the current CLSI breakpoint 
(64 μg/mL), and 7 exhibited intermediate resistance (MIC 
16 or 32 μg/mL). Three isolates (Mbandaka, Senftenberg, 
and Typhimurium) exhibited an ESBL phenotype accord-
ing to ceftazidime and cefotaxime MIC alone and with cla-
vulanate. Seven isolates exhibited the MDRAmpC pheno-
type, including 1 Agona, 2 Newport, 3 Typhimurium, and 
1 Uganda. According to current CLSI guidelines, 1 isolate 
(ser. Senftenberg) was fully resistant to ciproﬂ  oxacin, cef-
triaxone, ceftazidime, and cefotaxime.
The mechanisms responsible for resistance and de-
creased susceptibility are shown in Table 4. Some mech-
anisms for some of the isolates are presented elsewhere 
(3,17,18). At least 1 gyrA mutation was found in 26 of 27 
isolates. A gyrA mutation at codon 83 only was found for 
11 isolates; a mutation at codon 87 only was found for 3; 
mutations at both codons were found for 12. No functional 
mutations were detected in gyrB or parE genes. All Senften-
berg isolates had parC mutations (S80I and T57S), and 6 
other isolates had the T57S mutation. In addition to the 
T57S mutation in parC, the Mbandaka isolate contained a 
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Table 1. NARMS non-Typhi Salmonella serotypes with decreased susceptibility to quinolones and extended-spectrum cephalosporins, 
United States, 1996–2004* 
Serotype 
Year  No. that met MIC criteria/total tested (%)  Senftenberg Typhimurium Newport  Enteritidis Other  (no.) 
1996 0/1,324 (0) 
1997 1/1,301 (0.08) 1
1998 1/1,460 (0.07) 1
1999 1/1,497 (0.07) 1
2000 4/1,377 (0.29) 2 1 1
2001 4/1,419 (0.28)  2 1 Haifa (1) 
2002 5/2,008 (0.25)  1 2 1 Mbandaka (1) 
2003 4/1,864 (0.21)  2 1 Agona (1) 
2004 7/1,793 (0.39)  3 1 1 Saintpaul (1), 
Uganda (1) 
Total 27/14,043 (0.19) 11 6 3 2 5
*NARMS, National Antimicrobial Resistance Monitoring System. Reduced susceptibility to quinolones and extended-spectrum cephalosporins defined as 
MIC >32 μg/mL for nalidixic acid or >0.12 μg/mL for ciprofloxacin and >2 μg/mL for ceftiofur or >2 μg/mL for ceftriaxone. RESEARCH
plasmid-mediated qnrB2 gene and has been described (13). 
Four isolates contained aac(6′)-Ib, but none contained the 
ciproﬂ  oxacin-modifying aac(6′)-Ib-cr variant.
Nine AmpC phenotype isolates produced β-lactamase 
with a pI >8.4 (Table 4); 8 contained blaCMY-2, but the 
Senftenberg strain contained a blaCMY-23 gene (GenBank 
accession no. DQ463751) identical to that found in an E. 
coli isolate (GenBank accession no. DQ438952). This gene 
differs from blaCMY-2 by 1 amino acid. Three of the blaCMY-
positive isolates, including the strain positive for blaCMY-23, 
also contained blaTEM-1b. The Mbandaka isolate was positive 
for blaSHV-30 with pI 7.0 (33) and also produced an enzyme 
with a pI 7.6, the nature of which is still under study. Two 
isolates (1 Senftenberg and 1 Typhimurium) contained 
blaSHV-12, and both also contained blaOXA and blaTEM-1 genes. 
Of the 11 Senftenberg isolates, 10 contained blaOXA-1 (n = 9) 
or blaOXA-9 (n = 1). No isolates contained blaCTX-M genes.
Discussion
Fluoroquinolone and extended-spectrum cephalospo-
rin coresistance is rare; however, the appearance of this 
phenotype in 2 commonly isolated serotypes from humans 
(Typhimurium and Newport) is concerning. Sporadic in-
fections are alarming, but if clonal expansion of an iso-
late with this phenotype were to take place, as occurred 
with Salmonella ser. Typhimurium DT104 and Newport-
MDRAmpC, the clinical consequences could be dramatic. 
Statistically signiﬁ  cant increases in resistance to nalidixic 
acid (odds ratio [OR] 6.7, 95% conﬁ  dence interval [CI] 
CI 2.6–17.7) and ceftiofur (OR 43.2, 95% CI 10.5–177.4) 
have been documented among non-Typhi Salmonella of 
human origin submitted to NARMS during 1996–2003 
(4). Of 202 nalidixic acid–resistant non-Typhi Salmonella 
collected by NARMS during 1996–2003, most were ser. 
Enteritidis (31%) or Typhimurium (10%). Most of the 
324 ceftiofur-resistant non-Typhi Salmonella collected by 
NARMS during the same time period were ser. Newport 
(56%) or Typhimurium (23%). A slightly broader geo-
graphic representation can be found in the SENTRY sur-
veillance project, which analyzed 786 Salmonella isolates 
(blood and stool) from medical facilities in Latin America 
and North America (including Canada) during 2001–2003 
(8). Of these, 11% were resistant to nalidixic acid, and 2% 
exhibited decreased susceptibility to ceftazidime, ceftriax-
one, or aztreonam.
Extended-spectrum cephalosporin-resistant Newport 
and Typhimurium isolates are typically obtained from 
community-acquired infections. Newport-MDRAmpC 
infections have been associated with consumption of con-
taminated beef and unpasteurized dairy products (34). Sal-
monella containing blaCMY genes have been isolated from 
ground chicken (Typhimurium DT208), turkey (Agona), 
and beef (Agona) purchased from retail outlets in the Wash-
ington DC area (35). In addition, cattle, chickens, turkeys, 
pigs, horses, and dogs have all been sources of blaCMY-
containing Salmonella, including common serotypes such 
as Typhimurium, Newport, and Heidelberg (26,36,37). 
Decreased susceptibility to ﬂ  uoroquinolones among Sal-
monella serotypes that typically carry blaCMY genes war-
rants exploration of factors that could select for decreased 
susceptibility to ﬂ  uoroquinolones in animal reservoirs and 
in the human host.
PFGE showed diversity within some serotypes and 
indistinguishable strains within others. PFGE diversity 
among 2 serotypes commonly associated with extended-
spectrum cephalosporin resistance (Newport and Ty-
phimurium) is not surprising, given that CMY-producing 
strains have been seen at least since the late 1990s. Isolates 
of ser. Enteritidis are highly clonal; therefore, PFGE-indis-
tinguishable patterns among isolates with no apparent epi-
demiologic link are not unusual. All PFGE-indistinguish-
able Senftenberg isolates from group 1 were isolated in the 
same state. Results for the Florida Senftenberg isolates are 
described elsewhere (16,18).
Salmonella ser. Senftenberg exhibiting decreased sus-
ceptibility to ﬂ  uoroquinolones has been associated with 
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nosocomial infections in healthcare facilities in the United 
States (18). All 11 isolates contained identical gyrA mu-
tations (S83Y and D87G) and parC mutations (T57S and 
S80I). These parC mutations have been identiﬁ  ed in sev-
eral Salmonella serotypes including Senftenberg (38). Ten 
Senftenberg isolates included in this study contained blaOXA 
genes; the blaOXA-negative Senftenberg strain contained a 
blaCMY-23 mechanism of extended-spectrum cephalosporin 
resistance. Acquisition of a blaCMY gene by a traditionally 
nalidixic acid–resistant serotype warrants further epide-
miologic and laboratory investigation. The blaOXA-1 gene 
has been identiﬁ  ed in Salmonella ser. Typhimurium and is 
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reported to be carried by an integron (39); blaOXA-9 has been 
associated with Tn1331 (40).
The epidemiology of Salmonella with decreased sus-
ceptibility to ﬂ  uoroquinolones is relatively well character-
ized, as is that of Salmonella with blaCMY-mediated extend-
ed-spectrum cephalosporin resistance. Conversely, little is 
known about the events leading to quinolone and extended-
spectrum cephalosporin coresistance and the epidemiology 
of these infections in humans. Patients with Salmonella 
infections who exhibit decreased susceptibility to both an-
timicrobial drug classes should be interviewed to determine 
risk factors and the effects of antimicrobial drugs and other 
potential selective factors on this phenomenon.
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